Be Clinical has closed its third round of funding in 15 months, a cadence that says as much about investor appetite for India's clinical anti-ageing category as it does about the brand itself.

The direct-to-consumer skincare company announced on Aug 22, 2026 that it had raised Rs 21 crore, roughly $2.2 million, in a seed extension led by consumer-focused venture firm Sauce. Existing investor V3 Ventures participated, alongside a set of angels: Mokobara founders Sangeet Agrawal and Navin Parwal, Reckitt senior vice president Arjun Purkayastha, and Shaunak Chirayu Amin. No valuation was disclosed.

What the company sells

Be Clinical was founded by Hemangi Dhir and launched in May 2025 after about two years of formulation work. The positioning is deliberately narrow: anti-ageing, dermatologically active, clinically tested, built for Indian skin rather than adapted from Western ranges. The catalogue is short and treatment-led — the PlumpX and FirmX serums, Revive 10 Eye Cream and a Neck Repair Cream.

What differentiates it commercially is ownership of the stack. Manufacturing was brought in-house early and clinical testing is run internally, unusual for a brand this young, and it is the detail the lead investor cited. Zoeb Ali Khan, a vice president at Sauce, said longevity is expanding into how people look and feel, and that Be Clinical is capturing that shift through a full-stack model. Sales run through the company's own site and the Amazon and Flipkart marketplaces.

The numbers behind the round

Reported metrics are thin. The company says it has fulfilled about 1.2 lakh orders, or 120,000, since launch, and describes repeat purchase rates as healthy without publishing a figure. Revenue, gross margin and burn were not disclosed in any coverage of the round.

The funding history is clearer. Be Clinical raised Rs 2 crore in May 2025 led by Titan Capital, with P-TAL founder Aditya Agarwal joining, then Rs 6 crore in January 2026 led by V3 Ventures with Titan Capital following. This extension takes the total to roughly Rs 29 crore. That it is an extension rather than a Series A is the meaningful signal: the company is buying capacity and time, not pricing a growth round, and it comes without a disclosed step-up.

Why the timing matters

India's beauty and personal care market has been crowded for years, but the clinical and actives segment is where pricing power sits and where legacy FMCG distribution matters least. A brand can build credibility on ingredient claims and repeat purchase rather than shelf presence, which is why capital keeps finding labels barely a year old in this shelf.

The money goes to R&D and clinical testing, more manufacturing capacity, expansion from skincare into body and haircare, hiring, and new markets. That expansion is the item to watch. Broadening the portfolio is how a single-category brand justifies a Series A, but it also thins the focus that made the anti-ageing positioning legible in the first place. The angel list, weighted toward operators from Mokobara and Reckitt, suggests the backers are thinking about brand building and category width rather than a quick channel play.

Source

Indian Startup News — "D2C skincare brand Be Clinical raises Rs 21 crore in seed extension round led by Sauce"